Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 10/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23711746 | 1.00 | KHK (0.61) | KHKMAPTADRB1LMNATP53 | |
| SCHEMBL23734198 | 0.85 | GPR119 (0.59) | KHKMAPTLMNATP53 | |
| SCHEMBL31278709 | 0.84 | ADRB1 (0.63) | KHKMAPTADRB1TP53ALDH1A1 | |
| SCHEMBL23711751 | 0.84 | ADRB1 (0.63) | KHKMAPTADRB1TP53ALDH1A1 | |
| SCHEMBL23711719 | 0.81 | KHK (0.48) | KHKMAPTLMNAALDH1A1 | |
| SCHEMBL31280556 | 0.81 | KHK (0.48) | KHKMAPTLMNAALDH1A1 | |
| SCHEMBL23711728 | 0.81 | ADRB1 (0.58) | KHKMAPTADRB1TP53ALDH1A1 | |
| SCHEMBL31279811 | 0.81 | ADRB1 (0.58) | KHKMAPTADRB1TP53ALDH1A1 | |
| SCHEMBL23734200 | 0.80 | GPR119 (0.59) | KHKMAPTLMNATP53 | |
| SCHEMBL23711736 | 0.80 | KHK (0.49) | KHKMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177348-A1 | Methods for Fructokinase Meditation of Alcohol Craving and Alcohol Induced Liver Disease | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-06-05 | — | — | US | disclosed |
| US-12161621-B2 | Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2024-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12161621-B2 | Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease | KHK, GCK, FN3K | KHK 1/4885MAPT 1991/4885ADRB1 1244/4885 |
| US-20250177348-A1 | Methods for Fructokinase Meditation of Alcohol Craving and Alcohol Induced Liver Disease | KHK, GCK, FN3K | KHK 1/4885MAPT 1117/4885ADRB1 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.